Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 7,475 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 44.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 9,184 shares of the medical research company's stock after selling 7,475 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in IQVIA were worth $2,125,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. CWM LLC boosted its position in IQVIA by 5.8% during the third quarter. CWM LLC now owns 3,773 shares of the medical research company's stock valued at $742,000 after purchasing an additional 207 shares during the last quarter. HB Wealth Management LLC raised its holdings in shares of IQVIA by 21.7% during the 3rd quarter. HB Wealth Management LLC now owns 1,588 shares of the medical research company's stock valued at $312,000 after purchasing an additional 283 shares in the last quarter. DAVENPORT & Co LLC lifted its stake in shares of IQVIA by 13.9% in the 3rd quarter. DAVENPORT & Co LLC now owns 21,479 shares of the medical research company's stock valued at $4,226,000 after purchasing an additional 2,615 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. lifted its stake in shares of IQVIA by 9.1% in the 3rd quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,054 shares of the medical research company's stock valued at $207,000 after purchasing an additional 88 shares during the last quarter. Finally, Strategic Blueprint LLC raised its holdings in IQVIA by 9.9% during the third quarter. Strategic Blueprint LLC now owns 2,965 shares of the medical research company's stock valued at $583,000 after buying an additional 266 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IQV has been the subject of a number of analyst reports. Truist Financial boosted their price objective on shares of IQVIA from $286.00 to $297.00 and gave the stock a "buy" rating in a research note on Tuesday, February 27th. UBS Group raised their price target on IQVIA from $240.00 to $300.00 and gave the company a "buy" rating in a research report on Thursday, February 15th. Barclays raised their price target on IQVIA from $260.00 to $265.00 and gave the company an "overweight" rating in a research report on Thursday, February 15th. Leerink Partnrs reaffirmed an "outperform" rating on shares of IQVIA in a research report on Monday, February 26th. Finally, BTIG Research started coverage on IQVIA in a research report on Tuesday, February 13th. They issued a "buy" rating and a $285.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $256.80.

IQVIA Trading Up 3.2 %

IQV stock traded up $7.40 during trading on Tuesday, hitting $238.74. The company had a trading volume of 1,112,773 shares, compared to its average volume of 965,501. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. The firm has a 50-day moving average price of $245.08 and a 200-day moving average price of $222.28. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The stock has a market cap of $43.33 billion, a price-to-earnings ratio of 32.74, a PEG ratio of 2.21 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. During the same quarter in the previous year, the business earned $2.54 EPS. The business's quarterly revenue was up 3.5% compared to the same quarter last year. As a group, analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Ari Bousbib sold 31,678 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares of the company's stock, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Ari Bousbib sold 31,678 shares of the company's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company's stock, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the company's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the transaction, the insider now directly owns 5,251 shares of the company's stock, valued at $1,313,642.67. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,285 shares of company stock valued at $10,331,003. Company insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.